<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Aojula A</submitter><funding>Sir Arthur Thompson Trust</funding><funding>Department of Neurosurgery, Washington University School of Medicine</funding><funding>Pediatric Hydrocephalus Association</funding><funding>Medical Research Council</funding><funding>National Institute for Health Research (NIHR)</funding><funding>University of Utah Vice President for Research</funding><funding>Department of Neurosurgery, University of Utah</funding><funding>Biotechnology and Biological Sciences Research Council</funding><pagination>9</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4888658</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>In an effort to develop novel treatments for communicating hydrocephalus, we have shown previously that the transforming growth factor-β antagonist, decorin, inhibits subarachnoid fibrosis mediated ventriculomegaly; however decorin's ability to prevent cerebral cytopathology in communicating hydrocephalus has not been fully examined. Furthermore, the capacity for diffusion tensor imaging to act as a proxy measure of cerebral pathology in multiple sclerosis and spinal cord injury has recently been demonstrated. However, the use of diffusion tensor imaging to investigate cytopathological changes in communicating hydrocephalus is yet to occur. Hence, this study aimed to determine whether decorin treatment influences alterations in diffusion tensor imaging parameters and cyt</pubmed_abstract><journal>Fluids and barriers of the CNS</journal><pubmed_title>Diffusion tensor imaging with direct cytopathological validation: characterisation of decorin treatment in experimental juvenile communicating hydrocephalus.</pubmed_title><pmcid>PMC4888658</pmcid><funding_grant_id>CL-2009-09-001</funding_grant_id><funding_grant_id>MR/K015184/1</funding_grant_id><funding_grant_id>MR/N019016/1</funding_grant_id><funding_grant_id>NIHR-CS-011-028</funding_grant_id><pubmed_authors>Gonzalez AM</pubmed_authors><pubmed_authors>Sinclair A</pubmed_authors><pubmed_authors>Botfield H</pubmed_authors><pubmed_authors>Abdullah O</pubmed_authors><pubmed_authors>Aojula A</pubmed_authors><pubmed_authors>Logan A</pubmed_authors><pubmed_authors>McAllister JP</pubmed_authors></additional><is_claimable>false</is_claimable><name>Diffusion tensor imaging with direct cytopathological validation: characterisation of decorin treatment in experimental juvenile communicating hydrocephalus.</name><description>&lt;h4>Background&lt;/h4>In an effort to develop novel treatments for communicating hydrocephalus, we have shown previously that the transforming growth factor-β antagonist, decorin, inhibits subarachnoid fibrosis mediated ventriculomegaly; however decorin's ability to prevent cerebral cytopathology in communicating hydrocephalus has not been fully examined. Furthermore, the capacity for diffusion tensor imaging to act as a proxy measure of cerebral pathology in multiple sclerosis and spinal cord injury has recently been demonstrated. However, the use of diffusion tensor imaging to investigate cytopathological changes in communicating hydrocephalus is yet to occur. Hence, this study aimed to determine whether decorin treatment influences alterations in diffusion tensor imaging parameters and cyt</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 May</publication><modification>2026-07-15T21:23:02.27Z</modification><creation>2026-07-09T10:13:37.403Z</creation></dates><accession>S-EPMC4888658</accession><cross_references><pubmed>27246837</pubmed><doi>10.1186/s12987-016-0033-2</doi></cross_references></HashMap>